









市場行情
/
股票
/
nasdaq-nmra
/

Neumora Therapeutics Inc

NMRA

1.780USD

-0.030-1.66%

收盤 12/26, 16:00（美東）報價延遲15分鐘

288.27M總市值

虧損本益比TTM



Neumora Therapeutics Inc

1.780

-0.030-1.66%

概覽公司財務分析

概覽

公司

財務

分析

關於 Neumora Therapeutics Inc 公司

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Neumora Therapeutics Inc簡介



公司代碼NMRA

公司名稱Neumora Therapeutics Inc

上市日期Sep 15, 2023

CEOBerns (Paul L)

員工數量110

證券類型Ordinary Share

年結日Sep 15

公司地址260 Arsenal Place, Suite 1

城市WATERTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02472

電話18577600900

網址https://neumoratx.com/

公司代碼NMRA

上市日期Sep 15, 2023

CEOBerns (Paul L)

Neumora Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+3.27%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+46.75%

Ms. Kristina M. Burow

Independent Director

47.72K

+72.78%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-8.09%

Dr. Joshua Pinto, Ph.D.

President

Mr. Matthew K. (Matt) Fust

Independent Director

Mr. Jason G. Duncan

Chief Legal and Administrative Officer

Dr. Maykin Ho, Ph.D.

Independent Director

-100.00%

Mr. David Piacquad

Independent Director

Mr. Alaa A. Halawa

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+3.27%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+46.75%

Ms. Kristina M. Burow

Independent Director

47.72K

+72.78%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-8.09%

Dr. Joshua Pinto, Ph.D.

President

Mr. Matthew K. (Matt) Fust

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Amgen Inc

21.46%

ARCH Venture Partners

20.54%

Berns (Paul L)

4.66%

SB Global Advisers Ltd

3.97%

MIC Capital Management UK LLP

2.71%

其他

46.66%

持股股東

佔比

Amgen Inc

21.46%

ARCH Venture Partners

20.54%

Berns (Paul L)

4.66%

SB Global Advisers Ltd

3.97%

MIC Capital Management UK LLP

2.71%

其他

46.66%

股東類型

持股股東

佔比

Venture Capital

21.66%

Investment Advisor

21.51%

Corporation

21.46%

Individual Investor

5.33%

Hedge Fund

3.79%

Investment Advisor/Hedge Fund

2.35%

Endowment Fund

2.01%

Research Firm

0.63%

Bank and Trust

0.03%

其他

21.23%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

293

86.79M

53.64%

-40.47M

2025Q2

288

142.02M

87.70%

-25.57M

2025Q1

283

144.00M

90.43%

+12.16M

2024Q4

249

161.18M

99.54%

+45.20M

2024Q3

201

148.65M

93.66%

+40.67M

2024Q2

179

142.61M

90.03%

+47.65M

2024Q1

154

133.89M

85.01%

+50.39M

2023Q4

108

122.49M

78.90%

+50.97M

2023Q3

110.63M

71.42%

+110.63M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Amgen Inc

35.37M

21.84%

Apr 10, 2025

ARCH Venture Partners

31.93M

19.72%

Nov 12, 2024

Berns (Paul L)

7.68M

4.74%

+242.77K

+3.27%

Apr 10, 2025

SB Global Advisers Ltd

6.54M

4.04%

Jun 30, 2025

MIC Capital Management UK LLP

2.23M

1.38%

Jun 30, 2025

Invus Public Equities Advisors, LLC

4.36M

2.69%

Jun 30, 2025

The Vanguard Group, Inc.

4.76M

2.94%

-562.13K

-10.56%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.50M

2.16%

+6.35K

+0.18%

Jun 30, 2025

Wellcome Trust

3.31M

2.04%

Jun 30, 2025

ICONIQ Capital, LLC

2.56M

1.58%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco Nasdaq Biotechnology ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.04%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

iShares Biotechnology ETF

0.02%

Schwab U.S. Small-Cap ETF

0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

iShares US Small-Cap Equity Factor ETF

Virtus LifeSci Biotech Clinical Trials ETF

Fidelity MSCI Health Care Index ETF

Schwab U.S. Broad Market ETF

Invesco Nasdaq Biotechnology ETF

佔比0.05%

ProShares Ultra Nasdaq Biotechnology

佔比0.04%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.02%

iShares Biotechnology ETF

佔比0.02%

Schwab U.S. Small-Cap ETF

佔比0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比0%

iShares US Small-Cap Equity Factor ETF

佔比0%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0%

Fidelity MSCI Health Care Index ETF

佔比0%

Schwab U.S. Broad Market ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Neumora Therapeutics Inc的前五大股東是誰？



Neumora Therapeutics Inc的前五大股東如下：
Amgen Inc
持有股份：35.37M
佔總股份比例：21.84%。
ARCH Venture Partners
持有股份：31.93M
佔總股份比例：19.72%。
Berns (Paul L)
持有股份：7.68M
佔總股份比例：4.74%。
SB Global Advisers Ltd
持有股份：6.54M
佔總股份比例：4.04%。
MIC Capital Management UK LLP
持有股份：2.23M
佔總股份比例：1.38%。